This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Major histocompatibility complex class II deficiency, Bare lymphocyte syndrome type II주조직적합성복합체Ⅱ형결핍

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D81.7 (MHC class II deficiency) | OMIM: 209920 (CIITA deficiency), 600006 (RFX5 deficiency), 601861 (RFXANK), 601062 (RFXAP) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsMHC class II deficiency, Bare lymphocyte syndrome type II (BLS II), HLA class II deficiency, MHC-II deficiency SCID
C. Adult onsetLikelihood of first onset in adulthood very low — typically presents with severe opportunistic infections within the first 6 months of life or in early infancy; survival into adulthood without treatment is extremely rare. Rarely, diagnosis in late childhood is possible with mild variant combinations.
1. History1985, first systematic description of BLS II by Griscelli et al. → 1994, identification of deficiencies of transcriptional regulator genes such as CIITA and RFX5 → 1997–2000, additional confirmation of RFXANK and RFXAP deficiencies → establishment of a classification system of 4 genotypes.
2. CausesVariants in the CIITA, RFX5, RFXANK, and RFXAP genes → abnormal transcriptional regulation of MHC II genes → loss of HLA-DR/DP/DQ expression → impaired positive selection of CD4+ T cells → severe combined immunodeficiency.
3. GeneticsAutosomal recessive (AR). 4 genotypes (type A: RFXANK, type B: CIITA, type C: RFX5, type D: RFXAP). High frequency in people of North African descent. Multiple founder variants reported.
4. General epidemiologyMore than about 100–150 cases worldwide. Concentrated in people of North African descent. Equal in males and females. Incidence about 1/500,000 (specific regions of North Africa) to 1/1,000,000.
5. PathophysiologyDefect in the MHC II transcriptional regulatory complex (RFX5/RFXANK/RFXAP + CIITA) → suppression of HLA-DR/DP/DQ transcription → loss of MHC II expression → impaired intrathymic positive selection of CD4+ T cells → Th cell deficiency → combined humoral and cellular immune abnormalities.
6. SymptomsSevere opportunistic infections in early life (PJP, CMV, cryptosporidial enteritis), hepatobiliary sclerosis, recurrent bacterial infections, failure to thrive, chronic diarrhea, autoimmune hepatitis.
7. SignsMarked reduction of CD4+ T cells, reduced or normal serum immunoglobulins, loss of HLA II (HLA-DR) expression on flow cytometry, reduced lymphocyte proliferative response.
8. ScreeningTREC screening (TREC reduced when CD4+ T cells are reduced), HLA II expression on flow cytometry, early genetic testing based on family history.
9. DiagnosisLymphocyte typing (CD4↓, loss of HLA II), T-cell function tests, immunoglobulin quantification, molecular genetic testing (CIITA/RFX5/RFXANK/RFXAP), liver function tests.
10. TreatmentHSCT (curative), prophylactic TMP-SMX and antifungals, IVIG, treatment of Cryptosporidium, management of hepatobiliary complications. Live vaccines absolutely contraindicated.
11. PrognosisWithout treatment, most die in childhood of severe infection. Long-term survival possible with early HSCT (60–80%). Hepatobiliary complications may persist after HSCT. Cryptosporidial sclerosing cholangitis may require liver transplantation.
12. PreventionGenetic counseling, PGT/prenatal diagnosis, linkage with newborn TREC screening, infection prevention, drinking water hygiene (prevention of Cryptosporidium), live vaccines contraindicated.
13. ReferencesReith W et al. MHC class II deficiency: from the molecular mechanisms to the clinic … and 9 other papers

1. History

The history of major histocompatibility complex (MHC) class II deficiency, that is, Bare lymphocyte syndrome type II (BLS II), dates back to the late 1970s to early 1980s, when European pediatric immunologists began observing infants lacking HLA molecule expression. In 1985, the team at Necker Children's Hospital in Paris, including Claude Griscelli, Anne Durandy, and Josiane Lisowska-Grospierre of France, systematically described pediatric immunodeficiency patients in whom expression of MHC II molecules (HLA-DR, HLA-DP, HLA-DQ) on lymphocytes was completely lost. This report presented CD4+ T-cell deficiency, reduced antibody responses, recurrent opportunistic infections, and normal or reduced serum immunoglobulins together. It laid the groundwork for understanding BLS II as a combined immunodeficiency rather than a simple lack of HLA expression, and thereafter the name Bare lymphocyte syndrome came to refer collectively to MHC I/II deficiencies.

In the 1990s, advances in molecular biology techniques led to a concerted effort to identify the cause of BLS II. It was found that the HLA II genes themselves (the genes encoding HLA-DR, HLA-DP, HLA-DQ) were not abnormal, but the upstream regulatory factors that control the transcription of these genes were lacking. In 1994 the CIITA (Class II transactivator) gene was identified as the master regulator of MHC II expression, and CIITA gene variants were found in some BLS II patients. In the same year the RFX5 gene (regulatory factor X 5) was identified as another cause, and RFXANK (RFX ankyrin repeat–containing) in 1997 and RFXAP (RFX-associated protein) in the early 2000s were identified as additional causative genes.

BLS II is thus classified into 4 genotypes by causative gene: type A, RFXANK deficiency; type B, CIITA deficiency; type C, RFX5 deficiency; type D, RFXAP deficiency. These four proteins are essential components of a transcriptional regulatory pathway made up of the RFX5-RFXANK-RFXAP trimeric complex, which binds to the X box and W box sequences in the promoter region of MHC II genes, and CIITA, which activates it. The key to understanding the molecular pathophysiology of BLS II is that deficiency of any one component of this pathway blocks MHC II gene transcription and produces the same clinical phenotype (loss of HLA II expression).

Epidemiologically, BLS II has been reported at a disproportionately high frequency in patients from North Africa (Morocco, Algeria, Tunisia, Libya), the result of consanguineous marriage practices combined with a concentration of founder variants in this region. In particular, RFXANK deficiency is reported to be the most common type (about 50–60%) among North African patients. The disease is managed as ICD-10 D81.7, by subtype in Orphanet ORPHA:42, and by separate numbers for its 4 subtypes in OMIM. Recently, with the discovery of new variants through next-generation sequencing (NGS), genotype-phenotype correlation studies have been actively conducted, and long-term follow-up data after hematopoietic stem cell transplantation are also accumulating.


2. Causes

The cause of BLS II (MHC class II deficiency) is pathogenic variants in the upstream transcription factor genes that regulate MHC II gene transcription. The genes encoding the MHC II proteins themselves (HLA-DR, HLA-DP, HLA-DQ) are normal, but one of the key components of the regulatory pathway that activates the transcription of these genes is deficient, blocking MHC II expression.

CIITA (Class II, Major Histocompatibility Complex, Transactivator) is the master transcriptional activator of MHC II gene expression. CIITA is a non-DNA binding transactivator that does not bind DNA directly but activates MHC II transcription by interacting with the RFX complex bound to MHC II gene promoters. The CIITA gene is located on chromosome 16 (16p13.13), and transcription is initiated from 4 different promoters, regulating cell type-specific and cytokine-inducible (IFN-γ-induced) expression. CIITA deficiency constitutes type B of BLS II.

RFX5, RFXANK (RFXB), and RFXAP bind one another to form the RFX trimer (RFX5-RFXANK-RFXAP heterotrimer), and this complex binds specifically to the X box sequence of MHC II promoters. The RFX complex interacts with CIITA to promote MHC II transcription. The RFX5 gene is located on chromosome 1 (1q21.2), RFXANK (=RFXB) on chromosome 19 (19p13.12), and RFXAP on chromosome 13 (13q14.3). Pathogenic variants in each gene interfere with formation or function of the RFX trimer, making recognition of the MHC II promoter impossible and blocking transcription.

Ultimately, when a homozygous or compound heterozygous variant occurs in any one of the four genes, transcription of the MHC II genes (HLA-DR, DP, DQ α and β chains) is globally suppressed. As a result, HLA-DR, HLA-DP, and HLA-DQ expression on the cell surface is completely lost. This loss of MHC II expression makes it impossible for cortical thymic epithelial cells to provide the MHC II-self peptide complexes essential for positive selection of CD4+ T cells in the thymus, and consequently thymic output of mature CD4+ T cells is markedly reduced. In the periphery as well, loss of MHC II expression on antigen-presenting cells (dendritic cells, macrophages, B cells) makes CD4+ T-cell activation by exogenous antigens impossible, resulting in combined immunodeficiency.


3. Genetics

BLS II follows an autosomal recessive (AR) mode of inheritance and is classified into 4 genotypes (complementation groups) according to the 4 causative genes.

Because deficiency of any of the 4 genes equally results in loss of MHC II expression, they form complementation groups, and when complementation occurs in cell fusion experiments, the cells can be classified into different groups. This property was used importantly for gene identification through complementation experiments in the 1990s. Reported variant types include missense, nonsense, splicing, and small insertions/deletions, and the North African founder variants are most common in RFXANK. Molecular genetic diagnosis is performed by NGS of a primary immunodeficiency panel that includes the 4 genes, or by WES, and carrier testing and genetic counseling are offered.


4. General epidemiology

BLS II (MHC class II deficiency) is a rare disease worldwide, but more cases have been reported than for BLS I. Since its first description in 1985, an estimated 150–200 or more cases had been reported worldwide in the academic literature by the early 2020s. The incidence is estimated at about 1 per million births or less, but there are also estimates that in specific regions of North Africa it may be as high as 1 per 500,000 births in that region because of consanguineous marriage and concentration of founder variants.

Geographically, it is disproportionately concentrated in patient populations from North Africa (Morocco, Algeria, Tunisia, Libya, Egypt) or of North African descent. BLS II patients have been reported in concentration at medical institutions in Western European countries with large North African immigrant populations, such as France and Belgium. It has also been reported in countries with high rates of consanguineous marriage, such as Turkey, Iran, and Saudi Arabia. In keeping with autosomal recessive inheritance, males and females can be equally affected.

In Korea, confirmed cases of BLS II are very rare. Korea is understood to have lower patient numbers and diagnosis rates for primary immunodeficiencies overall compared with Western countries, and rare types such as BLS II are even fewer. The introduction of newborn TREC screening and expansion of NGS molecular diagnostic infrastructure are expected to contribute to improved diagnosis rates. The number of patients registered under code D81.7 in the Korean primary immunodeficiency registry and the rare disease Special Copayment Reduction (V111) data is not publicly available but is expected to be extremely small.

Epidemiologically, BLS II is a combined immunodeficiency due to MHC II deficiency with a very severe clinical course, so most patients die in childhood without early HSCT. This is one reason for the high pre-HSCT mortality of BLS II patients in SCID registry cohorts. It is managed under Orphanet ORPHA:42 (MHC II deficiency as a whole) and codes for the 4 subtypes, and under the respective gene numbers in OMIM.


5. Pathophysiology

The pathogenesis of BLS II is understood as a cascade that starts from complete blockade of MHC II gene transcriptional regulation and leads to failure of intrathymic CD4+ T-cell maturation, impaired peripheral antigen presentation, and combined immunodeficiency.

Molecular mechanism of MHC II transcriptional regulation

Normally, the MHC II genes (HLA-DRα, DRβ, DPα, DPβ, DQα, DQβ) have conserved X box (X1, X2) and W box (or Y box) sequences in their promoter regions, and transcription is activated when specific transcription factors bind to these sequences. The RFX5-RFXANK-RFXAP trimer binds to the X box, and CIITA, interacting with this complex, recruits the general transcription machinery and induces RNA polymerase II binding to the promoter. This transcriptional regulation occurs constitutively in antigen-presenting cells (B cells, dendritic cells, macrophages) and is inducibly activated by IFN-γ stimulation in other cell types. In BLS II, deficiency of any one of RFXANK, CIITA, RFX5, or RFXAP blocks this entire transcriptional pathway, and consequently no MHC II protein is produced at all.

Impaired intrathymic CD4+ T-cell maturation

In the thymic cortex, immature T cells (CD4+CD8+ double-positive thymocytes) receive a positive selection signal when they bind with weak affinity to MHC II-self peptide complexes on the surface of cortical thymic epithelial cells (cortical TEC), and mature into CD4 single-positive (CD4+ SP) T cells. In BLS II, MHC II is not expressed on any cells, including thymic epithelial cells, so this positive selection signal is completely absent. As a result, CD4+ T cells die in the thymus (and, without negative selection, are sometimes not properly eliminated) or remain immature and are not exported to the periphery. Because of this, CD4+ T-cell counts in peripheral blood are markedly reduced.

Peripheral immune dysfunction

In the periphery as well, when MHC II is not expressed on the surface of antigen-presenting cells (dendritic cells, macrophages, B cells), presentation of exogenous antigens to CD4+ T cells becomes impossible. As a result, all immune responses dependent on CD4+ T helper (Th) cells are impaired. Specifically, B-cell class switch recombination, high-affinity antibody production, and somatic hypermutation in response to T cell-dependent antigens cannot occur, so IgG, IgA, and IgM production is reduced. In addition, because activation of CD8+ T cells also requires help from CD4+ T helper cells, cytotoxic T-cell responses are indirectly impaired as well. NK cell function is relatively preserved. Thus BLS II is classified as a combined immunodeficiency centered on CD4+ T-cell deficiency.

Cryptosporidium infection and sclerosing cholangitis

One of the characteristic complications in BLS II patients is chronic infection with Cryptosporidium (Cryptosporidium spp.). Cryptosporidium infects the epithelium of the small intestine and bile ducts; in immunocompetent people it causes self-limited diarrhea, but in BLS II patients it becomes chronic, causing persistent intestinal diarrhea and malabsorption, and invades the bile ducts, leading to sclerosing cholangitis. This is a serious complication that leads to elevated liver enzymes, bile duct strictures, cholestasis, and ultimately cirrhosis and liver failure. Because bile duct damage that has already progressed may remain even after successful HSCT, this complication has an important effect on the prognosis of BLS II.


6. Symptoms

The clinical symptoms of BLS II (MHC class II deficiency) are generally severe even compared with other SCID types and tend to appear from early life.

Opportunistic infections

Severe opportunistic infections occur repeatedly from within the first 6 months of life. Pneumocystis pneumonia (PJP) is the most common and lethal. Cryptosporidiosis is a particularly prominent complication in BLS II, causing chronic diarrhea, malabsorption, and wasting, and is a cause of sclerosing cholangitis. Cytomegalovirus (CMV) infection (pneumonia, retinitis, hepatitis), herpes simplex virus (HSV), varicella (risk of disseminated varicella), and EBV-related infections are frequent. Susceptibility to parasitic infections such as Giardia enteritis and isosporiasis (Isospora belli) is also increased. Bacterial infections include recurrent sepsis, meningitis, and pneumonia due to pneumococcus, Salmonella, Pseudomonas aeruginosa, and others.

Gastrointestinal symptoms and hepatobiliary complications

Chronic diarrhea and malabsorption appear from early on, and Cryptosporidium infection persistently invades the intestinal tract and bile ducts. Hepatobiliary complications include cholestatic jaundice, elevated liver enzymes, fatty liver, and sclerosing cholangitis due to Cryptosporidium infection. As sclerosing cholangitis progresses, it leads to secondary biliary cirrhosis and liver failure, and this complication may persist even after successful HSCT. In some patients it progresses to the point of requiring liver transplantation.

Systemic symptoms

As a result of recurrent infections and chronic diarrhea, failure to thrive (FTT) is marked and malnutrition worsens. Autoimmune hepatitis has been reported in BLS II patients, reflecting abnormal immune regulation. Some patients present with a severe immunodeficiency no different from SCID, progressing to fatal infection within the first few months of life.


7. Signs

The most characteristic laboratory finding of BLS II is complete loss of HLA class II (HLA-DR) expression on flow cytometry.

Physical findings

Failure to thrive (weight loss, growth retardation), oral thrush, cutaneous Candida infection, jaundice (with hepatobiliary complications), and abdominal distension and ascites (with progression of cirrhosis) appear. With recurrent lung infections, crackles on auscultation, use of accessory muscles of respiration, and reduced oxygen saturation are observed. Lymph nodes are small or not palpable, and hepatosplenomegaly may appear.

Laboratory findings

Peripheral blood flow cytometry characteristically shows a marked reduction in CD4+ T cells (< 200/μL in severe cases, often < 50/μL). CD8+ T cells are normal or mildly reduced, and B cells (CD19+) are normal. Serum immunoglobulins are normal initially but may gradually decline, with reductions in IgA and IgM relatively prominent. T-cell function testing (PHA-stimulated proliferative response) shows a marked reduction. The key finding is HLA-DR expression measured as negative on flow cytometry, while HLA class I expression remains normal, which is a point of differentiation from BLS I. On TREC analysis, TREC tends to decrease with the reduction in CD4+ T cells, but in early stages when CD8+ T cells are relatively preserved, the TREC reduction may not be prominent. Elevated ALP, GGT, and bilirubin on liver function tests suggest biliary complications.


8. Screening

Newborn screening for BLS II can capture some cases through reduced TREC due to reduced CD4+ T cells, but sensitivity varies with the degree of CD4+ T-cell reduction.

TREC-based newborn screening

Because CD4+ T cells are severely reduced in BLS II, TREC tends to be markedly reduced, so it is more likely than BLS I to be captured by TREC testing, the newborn screening test for SCID types. When low (negative) TREC is confirmed, it is promptly followed by lymphocyte typing, and HLA class II expression analysis (flow cytometry) is performed.

Family history-based screening and molecular genetic testing

When there is an affected sibling or carrier parents have been identified, lymphocyte immunophenotyping (CD4+/CD8+ T-cell ratio, HLA II expression) and targeted variant analysis of the 4 causative genes (CIITA, RFX5, RFXANK, RFXAP) are performed immediately after birth. When a founder variant is known in families of North African descent, rapid diagnosis is possible by targeted analysis.

Prenatal screening

The presence of the causative variant is confirmed by fetal DNA analysis through chorionic villus sampling (CVS) or amniocentesis, and PGT can also be considered.


9. Diagnosis

Diagnosis of BLS II proceeds in the order of clinical suspicion → HLA expression analysis → molecular genetic confirmation.

Step 1: lymphocyte typing and measurement of HLA II expression

After a reduction in CD4+ T cells is confirmed on flow cytometry, HLA-DR expression is measured using pan-HLA II antibodies (mainly anti-HLA-DR antibodies). The confirmatory finding of BLS II is complete loss of HLA-DR expression on peripheral blood lymphocytes and monocytes. HLA class I (HLA-A/B/C) should be preserved as normal.

Step 2: T-cell function tests and serum immunoglobulins

Lymphocyte proliferative responses to mitogen (PHA) and antigen stimulation are measured, and they are markedly reduced in BLS II. Serum IgG, IgA, and IgM are quantified and tracked over time to monitor for antibody decline.

Step 3: molecular genetic confirmation

Variants are confirmed by NGS of a primary immunodeficiency panel that includes the 4 causative genes (CIITA, RFX5, RFXANK, RFXAP) or by WES. In populations with known founder variants, rapid diagnosis is possible by targeted Sanger analysis.

Step 4: liver function and gastrointestinal evaluation

Liver function tests (ALT, AST, ALP, GGT, bilirubin), abdominal ultrasound (evaluation of hepatobiliary structures), confirmation of intestinal Cryptosporidium infection (stool antigen test, PCR, small bowel biopsy), and evaluation of bile duct strictures by endoscopic retrograde cholangiopancreatography (ERCP) or MRCP are performed.

Differential diagnosis

Differentiation is needed from BLS I (MHC I deficiency, reduced CD8+, loss of HLA I), other SCID types (RAG1/2, JAK3, IL2RG, etc.), DiGeorge syndrome (22q11.2 deletion), and acquired immunodeficiency (excluding HIV).


10. Treatment

The curative goal of BLS II treatment is immune reconstitution through HSCT, and prevention of opportunistic infections and management of hepatobiliary complications are the core of supportive treatment.

Hematopoietic stem cell transplantation (HSCT)

HSCT is the only curative treatment for BLS II. Transplantation from an HLA-matched sibling donor is ideal, and when such a donor is difficult to find, transplantation from an unrelated HLA-matched donor or a haploidentical donor is also attempted. With successful HSCT, immune cells with normal MHC II expression are reconstituted, and CD4+ T cells and antibody responses recover. As for conditioning, because the risk of graft rejection is low in BLS II due to reduced CD4+ T cells, reduced-intensity (RIC) regimens are also tried. Even after successful transplantation, Cryptosporidium sclerosing cholangitis that has already developed may not fully resolve.

Prophylactic anti-infective treatment

TMP-SMX (PJP prophylaxis), antifungals (fluconazole), antivirals (ganciclovir, preemptive CMV treatment), IVIG (regular administration), an isolated environment, and absolute contraindication of live vaccines. To prevent Cryptosporidium, drinking unfiltered water (including water and swimming pool water) is strictly prohibited, and only purified drinking water should be used. When cryptosporidiosis is confirmed, nitazoxanide is tried as treatment, but its effect is limited in the immunodeficient state.

Management of hepatobiliary complications

Ursodeoxycholic acid (UDCA) is given for sclerosing cholangitis and cholestasis, and for biliary strictures, endoscopic balloon dilation or percutaneous drainage is considered. When cirrhosis has progressed, liver transplantation may be considered.


11. Prognosis

The prognosis of BLS II is severe; without treatment, most patients die of recurrent opportunistic infections in childhood (before age 2–5). Cryptosporidium sclerosing cholangitis is also one of the causes of early death.

Prognosis after HSCT: when early HSCT (before infectious complications develop) is performed, 3- to 5-year survival rates of about 60–80% are reported. Prognosis is best with HLA-matched sibling donor transplantation and slightly lower with unrelated donor transplantation. When CD4+ T-cell reconstitution and recovery of HLA II expression are achieved after HSCT, recurrent infections decrease markedly and immune function normalizes.

Prognosis of hepatobiliary complications: when Cryptosporidium infection has already occurred before HSCT and sclerosing cholangitis has progressed, bile duct damage may persist or worsen even after successful HSCT. Some patients require liver transplantation. This emphasizes that prompt HSCT (before cryptosporidial infection) is decisive in BLS II.

Management of long-term survivors: in patients with successful HSCT, chronic GVHD, PTLD, endocrine dysfunction, growth and development, and similar issues are followed regularly. Liver function and bile duct status are also included among long-term monitoring items.


12. Prevention

Prevention of BLS II is organized into reduction of genetic risk, early diagnosis, infection prevention, and management of complications.

Primary prevention: genetic counseling and PGT/prenatal diagnosis

Carrier parents of an affected child are informed of the 25% risk of an affected child in the next pregnancy and offered the options of PGT or prenatal genetic diagnosis (CVS/amniocentesis). When an RFXANK founder variant has been identified in a family of North African descent, prenatal targeted analysis can be done relatively quickly.

Secondary prevention: newborn screening and early treatment

Including TREC-based newborn screening, early diagnosis by early lymphocyte typing and HLA II expression testing in high-risk families, followed by immediate preparation for HSCT. After diagnosis and until HSCT, TMP-SMX, antifungals, IVIG, an isolated environment, avoidance of live vaccines, and drinking water filtering (prevention of Cryptosporidium) are strictly implemented.

Tertiary prevention: minimizing complications

Includes drinking water hygiene education to prevent cryptosporidial infection (use of reverse osmosis filters, boiled water), regular liver function monitoring, and early management of biliary complications. Long-term immune function, growth and development, and endocrine function are evaluated regularly after HSCT.


13. References

  1. Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nature Reviews Immunology. 2005;5(10):793–806. DOI: 10.1038/nri1708. PMID: 16200082.

  2. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes & Development. 2000;14(9):1156–1166. PMID: 10809673.

  3. Villard J, Masternak K, Lisowska-Grospierre B, et al. MHC class II deficiency: a disease of gene regulation. Medicine. 2001;80(6):405–418. DOI: 10.1097/00005792-200111000-00007. PMID: 11704713.

  4. Ouederni M, Vincent QB, Frange P, et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood. 2011;118(19):5108–5118. DOI: 10.1182/blood-2011-03-343608. PMID: 21878676.

  5. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annual Review of Immunology. 1996;14:301–331. DOI: 10.1146/annurev.immunol.14.1.301. PMID: 8717518.

  6. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.

  7. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annual Review of Immunology. 2001;19:331–373. DOI: 10.1146/annurev.immunol.19.1.331. PMID: 11244040.

  8. Barbouche MR, Azzari C, Casanova JL, et al. Hematopoietic stem-cell transplantation in MHC class II deficiency: a single-center experience. Bone Marrow Transplantation. 2001;27(8):833–838. DOI: 10.1038/sj.bmt.1702884. PMID: 11477444.

  9. Sloan SR, Barbour VM, Puck JM, Buckley RH. Combined immunodeficiency: a report of affected siblings. Pediatrics. 2003;112:e73–e78. DOI: 10.1542/peds.112.1.e73. PMID: 12837917.

  10. Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. Journal of Clinical Immunology. 2020;40(1):66–81. DOI: 10.1007/s10875-019-00722-4. PMID: 32048120.